ArticleCellular and molecular life sciences : CMLS2025
Inhibition of FXIIa attenuates kidney fibrosis in mice with unilateral ureteral obstruction.
Article in Cellular and molecular life sciences : CMLS, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Renal fibrosis is induced by hyperactive Wnt/β-catenin pathway via microbial-mediated tryptophan metabolism-driven AhR signaling in rodents and humans.Cellular and molecular life sciences : CMLS · 2026Article
- Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Kidney fibrosis is a common manifestation of chronic kidney diseases, with parenchymal tissue scarring serving as a histologic predictor of functional deterioration. Considering the relationships between contact-phase system activation and renal fibrosis as well as potential direct profibrotic activities of factor XII (FXII), we hypothesized that FXII inhibition with an anti-FXII/activated FXII (FXIIa) antibody (3F7) demonstrates therapeutic efficacy in a mouse model of unilateral ureteral obstruction (UUO). Treatment of UUO mice with 3F7 attenuated kidney fibrosis, as evidenced by preserved tissue structure, decreased deposition of collagen, and diminished apoptosis, but increased proliferation of tubular epithelial cells. No effect was observed with the administration of C1 esterase inhibitor, which serves as a primary plasma inhibitor of FXIIa and kallikrein. Transcriptome analysis revealed that 3F7 therapy predominantly affects stress-activated protein kinase signaling cascades and signal transduction in response to DNA damage. Exposure of renal epithelial cells to FXII or FXIIa triggered p21 expression in an Akt- and ERK1/2-dependent manner. Accordingly, treatment of UUO mice with 3F7 reduced numbers of p21
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.